Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | +3.92% | +2.58% | -19.29% |
29/04 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
28/03 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.29% | 26.32M | |
+0.67% | 42.4B | |
+46.40% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics : HC Wainwright Upgrades Iterum Therapeutics to Buy From Neutral; Price Target is $2.50